Healthcare providers across Canada will soon be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.®
This partnership integrates MyMeds&Me’s validated safety data capture solution into Auxita, enabling healthcare providers, patient support programs and pharmaceutical companies to capture and manage data more efficiently.
MyMeds&Me® is a global organization that provides an established end-to-end pharmacovigilance solution to simplify adverse event and product quality data capture. Its drug safety platform, Reportum, is used by pharmaceutical companies around the world to standardize data capture, streamline downstream processes and provide real-time access to complete, relevant safety information.
“Auxita is pleased to expand our service offering to enhance the management of safety data, captured at source from healthcare providers,” says Matt Cahill, CEO of Auxita. “Through our EMR and EHR-integrated platform, we provide an intuitive and standardized digital process to collect data and manage the flow of information throughout the patient journey. This partnership will offer patient support programs real-time access and enhanced visibility to key safety information.”
“Robust pharmacovigilance relies on a comprehensive body of complete, structured, and timely data. Therefore, it is critical that we make safety reporting really easy and intuitive for both physicians and patient support program staff whether in the office or out in the field” says Dr. Andrew Rut, CEO and founder of MyMeds&Me. “Our partnership with Auxita enables efficient capture of standardized information for our clients so they can accelerate safety insights.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.